EORTC 2011

Data from five studies of cabozantinib were presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference was held in San Francisco, November 12^th – 16^th, 2011.

Data Presentations

Title	Date
Efficacy and Tolerability of Cabozantinib at Lower Dose: A Dose Finding Study in Men with Castration-Resistant Prostate Cancer and Bone Metastases (Abstract A90)	Sunday, November 13, 2011 - 12:30pm PST
Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone (Abstract A233)	Sunday, November 13, 2011 - 12:30pm PST
Cabozantinib (XL184) reduces pain symptoms in patients (pts) with castration resistant prostate cancer (CRPC) and bone metastases: Results from a phase 2 non-randomized extension cohort (Abstract B57)	Monday, November 14, 2011 - 12:30pm PST
Cabozantinib effects on bone metastasis: Computer-aided quantitative bone scan assessment of prostate cancer treatment response (Abstract B114)	Monday, November 14, 2011 - 12:30pm PST
A phase 1 multiple ascending dose study of cabozantinib (XL184) monotherapy in Japanese patients with advanced solid tumors (Abstract C26)	Tuesday, November 15, 2011 - 12:30pm PST